HALO logo
halo search icon
Citius Pharmaceuticals Inc
Citius Pharmaceuticals Inc
CTXR · NAS

Citius Pharmaceuticals Inc

US$0.67

Price Arrow0.093 (16.05%)
21/05/2026 04:00:00 PM
All-CompaniesAll-ConsensusBig CandleHALO AllHALO GrowthHammer BullishNear SupportRecent Earnings downgrade
Consensus Score
Lock Icon/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

Citius Pharmaceuticals Inc Overview

CTXR Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

HALO Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Neutral

Valuation

Value

Lock Icon

Consensus

Lock Icon

Momentum

Price

Very Weak

Earnings

Very Weak

Growth

Earnings

Neutral

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

About CTXR

icon

Telephone

1.908.967.6677

icon

Address

1st floor, 11 Commerce Drive, Cranford, NJ 07016

Description

Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company was founded by Ralph Montrone, Leonard Mazur, Myron Holubiak on January 23, 2007 and is headquartered in Cranford, NJ.

CTXR Price Chart

Key Stats

Market Cap

US$15.92M

PE

0.80

EV/EBITDA

N/A

Dividends Overview

DIV Yield

0%

Franking

0%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.48 - 2.48

Trade Value (12mth)

US$387,617.00

1 week

-17.19%

1 month

-32.55%

YTD

-31.6%

1 year

-19.89%

All time high

937.55

Key Fundamentals

EPS 3 yr Growth

-41.20%

EBITDA Margin

0.00%

Operating Cashflow

-$27m

Free Cash Flow Return

-38.40%

ROIC

-54.10%

Interest Coverage

-143.10

Quick Ratio

0.10

Other Data

Shares Outstanding (Fully Diluted)

22m

HALO Sector

Healthcare

Next Company Report Date

17-Dec-26

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

USD

Short Sell (% of issue)

0.00

CTXR Announcements

Latest Announcements

DateAnnouncements
16 May 26
16 May 26
16 May 26
16 May 26
16 May 26

CTXR Fundamentals

Per Share Records

Historical data

Forecast data

USD2021202220232024202320242025202620272028
Per Share, Growth & Valuations
EPS (Basic)
$locklocklocklock-5.57-5.97-3.38locklocklock
EPS (Fully Diluted)
$locklocklocklock-5.57-5.97-3.38locklocklock
Growth
%locklocklocklock3.3-7.343.4locklocklock
PE
Xlocklocklocklock13.423.20.8locklocklock
EV/EBITDA
XlocklocklocklockN/AN/AN/Alocklocklock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

0%

Franking Level

0%

DPSg

N/A

Quality Yield

lock

Falling Divs over next 2

lock

Want to learn more?Frequently asked questions.
What is the current share price of Citius Pharmaceuticals Inc (CTXR:NAS)?
Halo FAQ
The current share price of Citius Pharmaceuticals Inc (CTXR:NAS) is USD$0.67.
What is the 52-week high share price for Citius Pharmaceuticals Inc (CTXR:NAS)?
Halo FAQ
The 52-week high share price for Citius Pharmaceuticals Inc (CTXR:NAS) is USD$2.48.
What is the 52-week low share price for Citius Pharmaceuticals Inc (CTXR:NAS)?
Halo FAQ
The 52-week low share price for Citius Pharmaceuticals Inc (CTXR:NAS) is USD$0.48.
What is the dividend yield for Citius Pharmaceuticals Inc (CTXR:NAS)?
Halo FAQ
Citius Pharmaceuticals Inc (CTXR:NAS) does not pay a dividend.
What was Citius Pharmaceuticals Inc (CTXR:NAS) last dividend payment?
Halo FAQ
Citius Pharmaceuticals Inc (CTXR:NAS) does not pay a dividend.
What is the franking level for Citius Pharmaceuticals Inc (CTXR:NAS)?
Halo FAQ
Citius Pharmaceuticals Inc (CTXR:NAS) has a franking level of 0.00%.
In which sector is Citius Pharmaceuticals Inc (CTXR:NAS) classified?
Halo FAQ
Citius Pharmaceuticals Inc (CTXR:NAS) is classified in the Healthcare.
What is the price-to-earnings (P/E) ratio for Citius Pharmaceuticals Inc (CTXR:NAS)?
Halo FAQ
The current P/E ratio for Citius Pharmaceuticals Inc (CTXR:NAS) is 0.80.

See beyond the curve.

One solution for research, investing and portfolio management.